Novo Nordisk CSO Outlines Next Diabetes Challenges
This article was originally published in Scrip
Executive Summary
Novo Nordisk, market leader for diabetes therapies, released data fora number of its products at the recent European Association for the Study of Diabetes meeting, but the company is still striving for domination of the entire diabetes spectrum, Mads Krogsgaard Thomsen, executive vice-president and chief science officer at Novo Nordisk, told Scrip in an exclusive interview on the side lines of the event.